NCT02858310 2026-03-09
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
Clinical Trials
17 trialsNCT03474497 2026-01-29
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
University of California, Davis
Phase 1/2 Active not recruiting
NCT05194735 2025-11-10
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Alaunos Therapeutics
Phase 1/2 Terminated
NCT01898793 2024-01-17
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Washington University School of Medicine
Phase 1/2 Terminated
NCT03287674 2023-03-01
TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer
Herlev Hospital
Phase 1/2 Completed
NCT00924326 2022-01-12
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02989714 2021-07-13
Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Completed
NCT02354690 2020-03-23
Vemurafenib and TIL Therapy for Metastatic Melanoma
Herlev Hospital
Phase 1/2 Completed
NCT02379195 2020-01-22
Peginterferon and TIL Therapy for Metastatic Melanoma
Herlev Hospital
Phase 1/2 Completed
NCT01550367 2020-01-02
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
University of Pittsburgh
Phase 1/2 Completed
NCT02153905 2019-06-17
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00303667 2017-12-28
Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Phase 1/2 Completed
NCT00625729 2017-12-28
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Masonic Cancer Center, University of Minnesota
Phase 1/2 Terminated
NCT02280811 2017-09-06
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00924287 2015-10-28
Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01273181 2015-10-28
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01592045 2015-09-23
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
United Therapeutics
Phase 1/2 Completed